This does not mean preeclampsia has one cause.
It shows what progress looks like when we move from describing a syndrome to arguing a defensible mechanism.
If you like these breakdowns, follow us.
Link: www.ahajournals.org/doi/10.1161/...
#Trinobia #Bioinformatics #Genomics
Instead of treating immune activation, placental defects, and vascular dysfunction as separate failures, the data show they can emerge from a shared transcriptional program, with VGLL3 upstream.
Preeclampsia affects ~1 in 10 pregnancies worldwide.
It is often described as a list of problems rather than a clear biological process.
This study takes a different approach.
🧬 A key discovery in preeclampsia broken down
A new Circulation paper moves the field forward by identifying VGLL3 as a regulator linking multiple disease features.
Here is why it matters 👇
This is not about slowing innovation.
It is about catching surprises earlier and making safety claims more defensible, for both ex vivo and in vivo editing.
Found this useful? Follow us for more clear breakdowns.
#Trinobia #Bioinformatics #GenomeEditing
Why researchers and developers should care 🧪
Sequencing depth, study design, and analysis choices are no longer optional details.
They are becoming regulatory expectations, not afterthoughts.
Why clinicians should care 👩⚕️🧬
Safety claims will increasingly be judged using genome wide evidence.
Rare off target events and structural variants are easy to miss without deep, well designed sequencing.
Key takeaway:
The FDA is now clearly saying that next generation sequencing should be the foundation for genome editing safety assessment.
That includes off target edits and overall genome integrity.
📣 FDA NEWS
The FDA just dropped a draft guidance on genome editing therapies.
We read it so you do not have to. Here is the short version 👇
The annotation of what rides alongside a driver oncogene deserves the same attention as the driver itself. Not as a secondary analysis, but as part of the primary question.
Full paper: www.nature.com/articles/s41...
#Trinobia #CancerResearch #Genomics #GBM
ecDNA amplicons appear across cancers, MYC, MDM2, CDK4.
If co-amplified lncRNAs can act independently of the driver in one context, the same logic applies elsewhere.
For years the assumption has been that EGFR is the whole story. When you only ask whether EGFR is active, you only find answers about EGFR.
The regulatory layers running in parallel stay invisible because the question never pointed at them.
HELDR, a lncRNA co-amplified with EGFR on ecDNA, drives GBM malignancy through its own epigenetic mechanism, entirely independent of EGFR signalling.
Targeting it rescued EGFR inhibitor efficacy in experimental models.
If EGFR amplification carries functional passengers, how many other driver oncogenes do the same?
A recent Nature Cell Biology paper on EGFR-amplified GBM opens that question up. 🧬
7/ In the next post, we get into what this finding opens up beyond GBM
Full paper: nature.com/articles/s41556-026-01924-w
Want to know more? Reach us at trinobia.com/contact
#RNAseq #Epigenetics #Bioinformatics
6/ None of these are exotic methods.
But together they reflect a discipline that gets cut under publish pressure: making sure your biological question, your data type, and your analytical resolution are all pointing in the same direction.
5/ Choice 3: knockdown + knockout + rescue.
With non-coding RNAs, expression correlation is almost never enough. You need to show the system breaks without it — and recovers when it returns.
4/ Choice 2: ChIRP-seq to show HELDR physically associates with chromatin at specific regulatory regions.
Not inferred from expression. Directly shown.
That distinction is the difference between a hypothesis and a mechanism.
3/ Choice 1: strand-aware RNA-seq + careful re-annotation.
Without it, HELDR likely gets misassigned or ignored entirely. Standard pipelines collapse complexity near dense amplicons. The biology was there. A blunter tool would have missed it.
2/ Last post covered HELDR — a co-amplified lncRNA that independently drives malignancy in EGFR-amplified glioblastoma.
Today: how the methodology made that finding possible in the first place.
1/ Why do some findings replicate and others fall apart?
Rarely the data. Almost always the methodological choices made before the data existed.
🧵
6/ Next up: the analytical and experimental approaches that made this finding possible, and why they are easy to get wrong.
Follow so you don't miss it, and reach out to us at Trinobia if you'd like to know more: trinobia.com/contact/
#Trinobia #Bioinformatics #Genomics
5/ The story is not that EGFR is irrelevant. It is that amplified oncogenes bring passengers with them, and some of those passengers are doing important work we simply have not been looking for. 🧬
Full paper: www.nature.com/articles/s41...
4/ The therapeutic implication is striking: targeting KAT7 or HELDR alongside EGFR inhibition markedly enhanced treatment efficacy in experimental models.
3/ HELDR is not just a genomic bystander. It drives tumor malignancy through its own mechanism, recruiting p300 to the KAT7 promoter and triggering epigenetic changes that activate gene programs critical for GBM aggressiveness, independently of EGFR signaling. 🔬
2/ A new paper in Nature Cell Biology asks a different question: what else gets amplified alongside EGFR, and does any of it matter?
The authors identified HELDR, a previously unannotated long non-coding RNA that is co-amplified with EGFR in a substantial fraction of GBM tumors
1/ EGFR is amplified in roughly 40% of glioblastomas, yet 80 to 90% of patients see little or no benefit from EGFR inhibitors.
We've studied this gene for decades. What if we've been looking at only half the picture?
#CancerResearch #ComputationalBiology
❓ As methods improve, do you feel optimistic that we can turn fragmented cfRNA into biologically meaningful insight, or still pushing against fundamental signal limitations?
#Trinobia #Bioinformatics #genomics #cfRNA #autoimmunity
Progress in genomics does not always come from discovering something new.
Sometimes it comes from finally being able to see what was already there.
Tools like REJOIN seq are designed to recover degraded cfRNA rather than filter it out.
This reflects a broader shift. Adapting methods to biology, not forcing biology into existing pipelines.